Lúcio P, Parreira A, van den Beemd M W, van Lochem E G, van Wering E R, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen J J, San Miguel J F
Department of Hematology, Portuguese Institute of Oncology, Lisbon.
Leukemia. 1999 Mar;13(3):419-27. doi: 10.1038/sj.leu.2401279.
During the last two decades, major progress has been made in the technology of flow cytometry and in the availability of a large series of monoclonal antibodies against surface membrane and intracellular antigens. Flow cytometric immunophenotyping has become a diagnostic tool for the analysis of normal and malignant leukocytes and it has proven to be a reliable approach for the investigation of minimal residual disease (MRD) in leukemia patients during and after treatment. In order to standardize the flow cytometric detection of MRD in acute leukemia, a BIOMED-1 Concerted Action was initiated with the participation of six laboratories in five different European countries. This European co-operative study included the immunophenotypic characterization and enumeration of different precursor and mature B cell subpopulations in normal bone marrow (BM). The phenotypic profiles in normal B cell differentiation may form a frame of reference for the identification of aberrant phenotypes of precursor-B cell acute lymphoblastic leukemias (precursor-B-ALL) and may therefore be helpful in MRD detection. Thirty-eight normal BM samples were analyzed with five different pre-selected monoclonal antibody combinations: CD10/CD20/CD19, CD34/CD38/CD19, CD34/CD22/CD19, CD19/CD34/CD45 and TdT/CD10/CD19. Two CD19- immature subpopulations which coexpressed B cell-associated antigens were identified: CD34+/CD22+/CD19- and TdT+/CD10+/CD19-, which represented 0.11 +/- 0.09% and 0.04 +/- 0.05% of the total BM nucleated cells, respectively. These immunophenotypes may correspond to the earliest stages of B cell differentiation. In addition to these minor subpopulations, three major CD19+ B cell subpopulations were identified, representing three consecutive maturation stages; CD19dim/CD34+/TdT+/CD10bright/CD22dim/CD45dim /CD38bright/CD20- (subpopulation 1), CD19+/CD34-/TdT-/CD10+/CD22dim/CD45+/CD38bright/ CD20dim (subpopulation 2) and CD19+/CD34-/TdT-/CD10-/CD22bright/CD45bright/ CD38dim/CD20bright (subpopulation 3). The relative sizes of subpopulations 1 and 2 were found to be age related: at the age of 15 years, the phenotypic precursor-B cell profile in BM changed from the childhood 'immature' profile (large subpopulations 1 and 2/small subpopulation 3) to the adult 'mature' profile (small subpopulation 1 and 2/large subpopulation 3). When the immunophenotypically defined precursor-B cell subpopulations from normal BM samples are projected in fluorescence dot-plots, templates for the normal B cell differentiation pathways can be defined and so-called 'empty spaces' where no cell populations are located become evident. This allows discrimination between normal and malignant precursor-B cells and can therefore be used for MRD detection.
在过去二十年中,流式细胞术技术以及针对表面膜和细胞内抗原的大量单克隆抗体的可获得性都取得了重大进展。流式细胞免疫表型分析已成为分析正常和恶性白细胞的诊断工具,并且已被证明是研究白血病患者治疗期间及治疗后微小残留病(MRD)的可靠方法。为了规范急性白血病中MRD的流式细胞术检测,启动了一项由五个不同欧洲国家的六个实验室参与的BIOMED-1协同行动。这项欧洲合作研究包括对正常骨髓(BM)中不同前体和成熟B细胞亚群的免疫表型特征分析和计数。正常B细胞分化过程中的表型谱可为识别前体B细胞急性淋巴细胞白血病(前体B-ALL)的异常表型提供参考框架,因此可能有助于MRD检测。使用五种预先选择的不同单克隆抗体组合对38份正常BM样本进行了分析:CD10/CD20/CD19、CD34/CD38/CD19、CD34/CD22/CD19、CD19/CD34/CD45和TdT/CD10/CD19。鉴定出两个共表达B细胞相关抗原的CD19-未成熟亚群:CD34+/CD22+/CD19-和TdT+/CD10+/CD19-,它们分别占总BM有核细胞的0.11±0.09%和0.04±0.05%。这些免疫表型可能对应于B细胞分化的最早阶段。除了这些较小的亚群外,还鉴定出三个主要的CD19+B细胞亚群,代表三个连续的成熟阶段;CD19dim/CD34+/TdT+/CD10bright/CD22dim/CD45dim /CD38bright/CD20-(亚群1)、CD19+/CD34-/TdT-/CD10+/CD22dim/CD45+/CD38bright/ CD20dim(亚群2)和CD19+/CD34-/TdT-/CD10-/CD22bright/CD45bright/ CD38dim/CD20bright(亚群3)。发现亚群1和亚群2的相对大小与年龄有关:在15岁时,BM中的表型前体B细胞谱从儿童期的“未成熟”谱(较大的亚群1和2/较小的亚群3)转变为成人的“成熟”谱(较小的亚群1和2/较大 的亚群3)。当将来自正常BM样本的免疫表型定义的前体B细胞亚群投影到荧光点图中时,可以定义正常B细胞分化途径的模板,并且没有细胞群的所谓“空白区域”变得明显。这允许区分正常和恶性前体B细胞,因此可用于MRD检测。